Cargando…
Safety of Amlodipine in Early Pregnancy
BACKGROUND: Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited. METHODS AND RESULTS: In the present study, we recruited 231 women with chronic hypertension, including those who received amlodipine or other antihypertensives during early pregna...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761676/ https://www.ncbi.nlm.nih.gov/pubmed/31345083 http://dx.doi.org/10.1161/JAHA.119.012093 |
_version_ | 1783454072847728640 |
---|---|
author | Mito, Asako Murashima, Atsuko Wada, Yoshinao Miyasato‐Isoda, Mai Kamiya, Chizuko A. Waguri, Masako Yoshimatsu, Jun Yakuwa, Naho Watanabe, Omi Suzuki, Tomo Arata, Naoko Mikami, Masashi Ito, Shinya |
author_facet | Mito, Asako Murashima, Atsuko Wada, Yoshinao Miyasato‐Isoda, Mai Kamiya, Chizuko A. Waguri, Masako Yoshimatsu, Jun Yakuwa, Naho Watanabe, Omi Suzuki, Tomo Arata, Naoko Mikami, Masashi Ito, Shinya |
author_sort | Mito, Asako |
collection | PubMed |
description | BACKGROUND: Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited. METHODS AND RESULTS: In the present study, we recruited 231 women with chronic hypertension, including those who received amlodipine or other antihypertensives during early pregnancy, and investigated frequencies of morphologic abnormalities in their 231 offspring. Specifically, we evaluated 48 neonates exposed to amlodipine in the first trimester (amlodipine group, Group A), 54 neonates exposed to antihypertensives other than amlodipine (other antihypertensive group, Group O), and 129 neonates not exposed to antihypertensives (no‐antihypertensive group, Group N). The number of morphologic abnormalities of offspring in each group were 2 in Group A (4.2%; 95% CI, 0.51–14.25); 3 in Group O (5.6%; 95% CI, 1.16–15.39) and 6 in Group N (4.7%; 95% CI, 1.73–9.85). The odds ratio of the primary outcome comparing Group A and Group O was 0.74 (95% CI: 0.118–4.621) and Group A and Group N was 0.89 (95% CI: 0.174–4.575). CONCLUSIONS: The odds of birth defects in Group A in the first trimester were not significantly different from those with or without other antihypertensives. |
format | Online Article Text |
id | pubmed-6761676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67616762019-09-30 Safety of Amlodipine in Early Pregnancy Mito, Asako Murashima, Atsuko Wada, Yoshinao Miyasato‐Isoda, Mai Kamiya, Chizuko A. Waguri, Masako Yoshimatsu, Jun Yakuwa, Naho Watanabe, Omi Suzuki, Tomo Arata, Naoko Mikami, Masashi Ito, Shinya J Am Heart Assoc Original Research BACKGROUND: Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited. METHODS AND RESULTS: In the present study, we recruited 231 women with chronic hypertension, including those who received amlodipine or other antihypertensives during early pregnancy, and investigated frequencies of morphologic abnormalities in their 231 offspring. Specifically, we evaluated 48 neonates exposed to amlodipine in the first trimester (amlodipine group, Group A), 54 neonates exposed to antihypertensives other than amlodipine (other antihypertensive group, Group O), and 129 neonates not exposed to antihypertensives (no‐antihypertensive group, Group N). The number of morphologic abnormalities of offspring in each group were 2 in Group A (4.2%; 95% CI, 0.51–14.25); 3 in Group O (5.6%; 95% CI, 1.16–15.39) and 6 in Group N (4.7%; 95% CI, 1.73–9.85). The odds ratio of the primary outcome comparing Group A and Group O was 0.74 (95% CI: 0.118–4.621) and Group A and Group N was 0.89 (95% CI: 0.174–4.575). CONCLUSIONS: The odds of birth defects in Group A in the first trimester were not significantly different from those with or without other antihypertensives. John Wiley and Sons Inc. 2019-07-26 /pmc/articles/PMC6761676/ /pubmed/31345083 http://dx.doi.org/10.1161/JAHA.119.012093 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Mito, Asako Murashima, Atsuko Wada, Yoshinao Miyasato‐Isoda, Mai Kamiya, Chizuko A. Waguri, Masako Yoshimatsu, Jun Yakuwa, Naho Watanabe, Omi Suzuki, Tomo Arata, Naoko Mikami, Masashi Ito, Shinya Safety of Amlodipine in Early Pregnancy |
title | Safety of Amlodipine in Early Pregnancy |
title_full | Safety of Amlodipine in Early Pregnancy |
title_fullStr | Safety of Amlodipine in Early Pregnancy |
title_full_unstemmed | Safety of Amlodipine in Early Pregnancy |
title_short | Safety of Amlodipine in Early Pregnancy |
title_sort | safety of amlodipine in early pregnancy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761676/ https://www.ncbi.nlm.nih.gov/pubmed/31345083 http://dx.doi.org/10.1161/JAHA.119.012093 |
work_keys_str_mv | AT mitoasako safetyofamlodipineinearlypregnancy AT murashimaatsuko safetyofamlodipineinearlypregnancy AT wadayoshinao safetyofamlodipineinearlypregnancy AT miyasatoisodamai safetyofamlodipineinearlypregnancy AT kamiyachizukoa safetyofamlodipineinearlypregnancy AT wagurimasako safetyofamlodipineinearlypregnancy AT yoshimatsujun safetyofamlodipineinearlypregnancy AT yakuwanaho safetyofamlodipineinearlypregnancy AT watanabeomi safetyofamlodipineinearlypregnancy AT suzukitomo safetyofamlodipineinearlypregnancy AT aratanaoko safetyofamlodipineinearlypregnancy AT mikamimasashi safetyofamlodipineinearlypregnancy AT itoshinya safetyofamlodipineinearlypregnancy |